Localized primary non-Hodgkin lymphoma of the breast

被引:60
作者
Ha, CS
Dubey, P
Goyal, LK
Hess, M
Cabanillas, F
Cox, JD
机构
[1] Univ Texas, MD Anderson Cancer Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Cancer Ctr, Dept Hematol, Houston, TX 77030 USA
[3] Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1998年 / 21卷 / 04期
关键词
lymphoma; breast; radiation therapy; chemotherapy; Ann Arbor stage; International Prognostic Index;
D O I
10.1097/00000421-199808000-00012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A single institution's experience with the treatment of localized primary lymphoma of the breast (PLB) was analyzed to understand the natural history of this disease and to identify major prognostic factors and optimal treatment. A retrospective analysis of 23 previously untreated patients who met the strict criteria of PLB from 1972 through 1994 was undertaken. All pathologic materials were reviewed and classified by the Working Formulation. The Ann Arbor stages (AASs) were: IE, 17 patients; IIE, five patients; TV, one patients (bilateral breast involvement without distant metastasis). Pathologic findings were: low grade, two patients; intermediate grade, 18 patients (17 with diffuse large-cell lymphoma (DLCL)); high grade, two patients; and unclassifiable, one patient. The treatments after biopsy or mastectomy were: radiation alone, two patients; chemotherapy alone, six patients; and combined-modality therapy, 13 patients. Two patients had mastectomy alone. Overall survival (OS) and relapse-free survival (RFS) were calculated actuarially. Univariate analyses were performed with patient age, treatment modality, AAS, size of the primary tumor (T stage), and International Prognostic Index (IPI) for the 17 patients with DLCL to define prognostic factors. The median follow-up for the surviving patients was 78 months (range, 45-220 months). The 5-year OS and RFS were 74% and 73%, respectively for all 23 patients, and 65% and 70%, respectively, for the 17 patients with DLCL. Statistically significant factors for OS for DLCL were AAS and IPI. Statistically significant factors for RFS were AAS and T stage. With modern staging evaluation and multiagent combination chemotherapy, localized primary non-Hodgkin lymphoma of the breast, especially diffuse large-cell type, has a prognosis as favorable as that of other DLCL. Ann Arbor stage was a significant factor for both OS and RFS.
引用
收藏
页码:376 / 380
页数:5
相关论文
共 35 条
[1]   Primary diffuse large B-cell lymphoma of the breast a clinicopathologic study of 31 cases [J].
Abbondanzo, SL ;
Seidman, JD ;
Lefkowitz, M ;
Tavassoli, FA ;
Krishnan, J .
PATHOLOGY RESEARCH AND PRACTICE, 1996, 192 (01) :37-43
[2]   MALIGNANT-LYMPHOMA OF THE BREAST - IMMUNOLOGICAL TYPE AND ASSOCIATION WITH LYMPHOCYTIC MASTOPATHY [J].
AOZASA, K ;
OHSAWA, M ;
SAEKI, K ;
HORIUCHI, K ;
KAWANO, K ;
TAGUCHI, T .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 97 (05) :699-704
[3]   NON-HODGKINS-LYMPHOMA INVOLVING THE BREAST [J].
ARBER, DA ;
SIMPSON, JF ;
WEISS, LM ;
RAPPAPORT, H .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (03) :288-295
[4]  
BEAHRS O, 1992, AM JOINT COMMITTEE C, P257
[5]   BREAST LYMPHOMAS - A CLINICOPATHOLOGICAL REVIEW [J].
BOBROW, LG ;
RICHARDS, MA ;
HAPPERFIELD, LC ;
DISS, TC ;
ISAACSON, PG ;
LAMMIE, GA ;
MILLIS, RR .
HUMAN PATHOLOGY, 1993, 24 (03) :274-278
[6]   MALIGNANT-LYMPHOMA OF THE BREAST - A STUDY OF 53 PATIENTS [J].
BRUSTEIN, S ;
KIMMEL, M ;
LIEBERMAN, PH ;
FILIPPA, DA ;
ROSEN, PP .
ANNALS OF SURGERY, 1987, 205 (02) :144-150
[7]  
COHEN PL, 1991, CANCER-AM CANCER SOC, V67, P1359, DOI 10.1002/1097-0142(19910301)67:5<1359::AID-CNCR2820670515>3.0.CO
[8]  
2-4
[9]  
COLTMAN CA, 1977, CANCER TREAT REP, V61, P1067
[10]  
DAO AH, 1992, AM SURGEON, V58, P792